Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

Flonza Isa; Eduardo Forleo‐Neto; Jonathan Meyer; Wenjun Zheng; Scott Rasmussen; Danielle Armas; Masaru Oshita; Cynthia Brinson; Steven Folkerth; Lori Faria; Ingeborg Heirman; Neena Sarkar; Bret J. Musser; Shikha Bansal; Meagan P. O’Brien; K. C. Turner; Samit Ganguly; Adnan Mahmood; Ajla Dupljak; Andrea T. Hooper; Jennifer D. Hamilton; Yun‐Ji Kim; Bari Kowal; Yuhwen Soo; Gregory P. Geba; Leah Lipsich; Ned Braunstein; George D. Yancopoulos; David M. Weinreich; Gary Herman

doi:10.1016/j.ijid.2022.06.045

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Repeat monthly administration of 1200 mg SC CAS+IMD was well-tolerated, demonstrated low immunogenicity, and showed a substantial risk reduction in COVID-19 occurrence.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Isa et al. (2022) studied this question.

synapsesocial.com/papers/69d76666b1cb92dd1bb8ae68 https://doi.org/10.1016/j.ijid.2022.06.045

View Full Paper

Ask AI

Bookmark

Share

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

Ask about this paper

Abstract

Discussion

Cite This Study

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading